The OAC is proud to share that Rhythm Pharmaceuticals, one of our long-time supporters and partners in research and advocacy, has renewed their membership on OAC’s Chairman’s Council at the Silver Level.

Rhythm is a biopharmaceutical company dedicated to changing how rare genetic diseases of obesity are diagnosed and treated. The company is also leading efforts to improve patient identification and diagnosis through genetic testing and deepen the community’s understanding of the ongoing impact and burden of disease on patients and caregivers.

The company’s precision medicine, IMCIVREE™ (setmelanotide), has been approved by the FDA for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to POMC, PCSK1 or LEPR deficiency confirmed by genetic testing. IMCIVREE™ is the first-ever FDA-approved therapy for these rare genetic diseases of obesity.

To learn more about Rhythm, visit

About OAC’s Chairman’s Council

The Chairman’s Council is OAC’s corporate level of membership. We invite both companies and individuals to join this prestigious group and show their public support of the OAC and patients. Our Chairman’s Council is an integral way of giving back to our cause and plays a key role in making the world a better place for people with obesity.

To learn more about OAC’s Chairman’s Council, click here.